Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
The Association Between Suicide-Related Media Coverage and Suicide: A Cross-Sectional Observational Study.

Archives of suicide research : official journal of the International Academy for Suicide Research

Hofstra E, Bakker M, Diepstraten CAM, Elfeddali I, Lucas MS, van Nieuwenhuizen C, van der Feltz-Cornelis CM.
PMID: 33275539
Arch Suicide Res. 2020 Dec 04;1-14. doi: 10.1080/13811118.2020.1851833. Epub 2020 Dec 04.

OBJECTIVE: To examine the association between the publication and content of suicide-related media reports and actual suicide in Noord Brabant, a province of the Netherlands.METHOD: Between April 2017 and March 2018, a retrospective cross-sectional observational study was conducted on...

Cite
Hofstra E, Bakker M, Diepstraten CAM, et al. The Association Between Suicide-Related Media Coverage and Suicide: A Cross-Sectional Observational Study. Arch Suicide Res. 2020;1-14doi: 10.1080/13811118.2020.1851833.
Hofstra, E., Bakker, M., Diepstraten, C. A. M., Elfeddali, I., Lucas, M. S., van Nieuwenhuizen, C., & van der Feltz-Cornelis, C. M. (2020). The Association Between Suicide-Related Media Coverage and Suicide: A Cross-Sectional Observational Study. Archives of suicide research : official journal of the International Academy for Suicide Research, 1-14. https://doi.org/10.1080/13811118.2020.1851833
Hofstra, Emma, et al. "The Association Between Suicide-Related Media Coverage and Suicide: A Cross-Sectional Observational Study." Archives of suicide research : official journal of the International Academy for Suicide Research vol. (2020): 1-14. doi: https://doi.org/10.1080/13811118.2020.1851833
Hofstra E, Bakker M, Diepstraten CAM, Elfeddali I, Lucas MS, van Nieuwenhuizen C, van der Feltz-Cornelis CM. The Association Between Suicide-Related Media Coverage and Suicide: A Cross-Sectional Observational Study. Arch Suicide Res. 2020 Dec 04;1-14. doi: 10.1080/13811118.2020.1851833. Epub 2020 Dec 04. PMID: 33275539.
Copy Download .nbib Format: NLM
Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review.

JAC-antimicrobial resistance

Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, Meijer AJM.
PMID: 34917943
JAC Antimicrob Resist. 2021 Dec 14;3(4):dlab184. doi: 10.1093/jacamr/dlab184. eCollection 2021 Dec.

BACKGROUND: Ototoxicity has been reported after administration of aminoglycosides and glycopeptides.OBJECTIVES: To identify available evidence for the occurrence and determinants of aminoglycoside- and glycopeptide-related ototoxicity in children.MATERIALS AND METHODS: Systematic electronic literature searches that combined ototoxicity (hearing loss, tinnitus...

Cite
Diepstraten FA, Hoetink AE, van Grotel M, et al. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. 2021;3(4):dlab184doi: 10.1093/jacamr/dlab184.
Diepstraten, F. A., Hoetink, A. E., van Grotel, M., Huitema, A. D. R., Stokroos, R. J., van den Heuvel-Eibrink, M. M., & Meijer, A. J. M. (2021). Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC-antimicrobial resistance, 3(4), dlab184. https://doi.org/10.1093/jacamr/dlab184
Diepstraten, F A, et al. "Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review." JAC-antimicrobial resistance vol. 3,4 (2021): dlab184. doi: https://doi.org/10.1093/jacamr/dlab184
Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, Meijer AJM. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. 2021 Dec 14;3(4):dlab184. doi: 10.1093/jacamr/dlab184. eCollection 2021 Dec. PMID: 34917943; PMCID: PMC8669239.
Copy Download .nbib Format: NLM
MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3.

Cell death and differentiation

Teh CE, Robbins AK, Henstridge DC, Dewson G, Diepstraten ST, Kelly G, Febbraio MA, Gabriel SS, O'Reilly LA, Strasser A, Gray DHD.
PMID: 32612106
Cell Death Differ. 2020 Dec;27(12):3374-3385. doi: 10.1038/s41418-020-0585-1. Epub 2020 Jul 01.

FOXP3

Cite
Teh CE, Robbins AK, Henstridge DC, et al. MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3. Cell Death Differ. 2020;27(12):3374-3385doi: 10.1038/s41418-020-0585-1.
Teh, C. E., Robbins, A. K., Henstridge, D. C., Dewson, G., Diepstraten, S. T., Kelly, G., Febbraio, M. A., Gabriel, S. S., O'Reilly, L. A., Strasser, A., & Gray, D. H. D. (2020). MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3. Cell death and differentiation, 27(12), 3374-3385. https://doi.org/10.1038/s41418-020-0585-1
Teh, Charis E, et al. "MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3." Cell death and differentiation vol. 27,12 (2020): 3374-3385. doi: https://doi.org/10.1038/s41418-020-0585-1
Teh CE, Robbins AK, Henstridge DC, Dewson G, Diepstraten ST, Kelly G, Febbraio MA, Gabriel SS, O'Reilly LA, Strasser A, Gray DHD. MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3. Cell Death Differ. 2020 Dec;27(12):3374-3385. doi: 10.1038/s41418-020-0585-1. Epub 2020 Jul 01. PMID: 32612106; PMCID: PMC7853142.
Copy Download .nbib Format: NLM
Evaluation of propofol anesthesia in morbidly obese children and adolescents.

BMC anesthesiology

Chidambaran V, Sadhasivam S, Diepstraten J, Esslinger H, Cox S, Schnell BM, Samuels P, Inge T, Vinks AA, Knibbe CA.
PMID: 23602008
BMC Anesthesiol. 2013 Apr 21;13:8. doi: 10.1186/1471-2253-13-8. eCollection 2013.

BACKGROUND: Poor characterization of propofol pharmacokinetics and pharmacodynamics in the morbidly obese (MO) pediatric population poses dosing challenges. This study was conducted to evaluate propofol total intravenous anesthesia (TIVA) in this population.METHODS: After IRB approval, a prospective study was...

Cite
Chidambaran V, Sadhasivam S, Diepstraten J, et al. Evaluation of propofol anesthesia in morbidly obese children and adolescents. BMC Anesthesiol. 2013;13:8doi: 10.1186/1471-2253-13-8.
Chidambaran, V., Sadhasivam, S., Diepstraten, J., Esslinger, H., Cox, S., Schnell, B. M., Samuels, P., Inge, T., Vinks, A. A., & Knibbe, C. A. (2013). Evaluation of propofol anesthesia in morbidly obese children and adolescents. BMC anesthesiology, 138. https://doi.org/10.1186/1471-2253-13-8
Chidambaran, Vidya, et al. "Evaluation of propofol anesthesia in morbidly obese children and adolescents." BMC anesthesiology vol. 13 (2013): 8. doi: https://doi.org/10.1186/1471-2253-13-8
Chidambaran V, Sadhasivam S, Diepstraten J, Esslinger H, Cox S, Schnell BM, Samuels P, Inge T, Vinks AA, Knibbe CA. Evaluation of propofol anesthesia in morbidly obese children and adolescents. BMC Anesthesiol. 2013 Apr 21;13:8. doi: 10.1186/1471-2253-13-8. eCollection 2013. PMID: 23602008; PMCID: PMC3644256.
Copy Download .nbib Format: NLM
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

Blood

Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, Dengler MA, Litalien V, MacRaild S, Chen M, Anstee NS, Reljić B, Gabriel SS, Djajawi TM, Riffkin CD, Aubrey BJ, Chang C, Tai L, Xu Z, Morley T, Pomilio G, Bruedigam C, Kallies A, Stroud DA, Bajel A, Kluck RM, Lane SW, Schoumacher M, Banquet S, Majewski IJ, Strasser A, Roberts AW, Huang DCS, Brown FC, Kelly GL, Wei AH.
PMID: 33824975
Blood. 2021 May 20;137(20):2721-2735. doi: 10.1182/blood.2020010167.

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemias. TP-53 controls apoptosis upstream of where BCL-2 and its prosurvival relatives, such as MCL-1, act. Therefore, targeting these prosurvival proteins could...

Cite
Thijssen R, Diepstraten ST, Moujalled D, et al. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021;137(20):2721-2735doi: 10.1182/blood.2020010167.
Thijssen, R., Diepstraten, S. T., Moujalled, D., Chew, E., Flensburg, C., Shi, M. X., Dengler, M. A., Litalien, V., MacRaild, S., Chen, M., Anstee, N. S., Reljić, B., Gabriel, S. S., Djajawi, T. M., Riffkin, C. D., Aubrey, B. J., Chang, C., Tai, L., Xu, Z., Morley, T., Pomilio, G., Bruedigam, C., Kallies, A., Stroud, D. A., Bajel, A., Kluck, R. M., Lane, S. W., Schoumacher, M., Banquet, S., Majewski, I. J., Strasser, A., Roberts, A. W., Huang, D. C. S., Brown, F. C., Kelly, G. L., & Wei, A. H. (2021). Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood, 137(20), 2721-2735. https://doi.org/10.1182/blood.2020010167
Thijssen, Rachel, et al. "Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias." Blood vol. 137,20 (2021): 2721-2735. doi: https://doi.org/10.1182/blood.2020010167
Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, Dengler MA, Litalien V, MacRaild S, Chen M, Anstee NS, Reljić B, Gabriel SS, Djajawi TM, Riffkin CD, Aubrey BJ, Chang C, Tai L, Xu Z, Morley T, Pomilio G, Bruedigam C, Kallies A, Stroud DA, Bajel A, Kluck RM, Lane SW, Schoumacher M, Banquet S, Majewski IJ, Strasser A, Roberts AW, Huang DCS, Brown FC, Kelly GL, Wei AH. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021 May 20;137(20):2721-2735. doi: 10.1182/blood.2020010167. PMID: 33824975; PMCID: PMC8138548.
Copy Download .nbib Format: NLM
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.

Nature reviews. Cancer

Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL.
PMID: 34663943
Nat Rev Cancer. 2022 Jan;22(1):45-64. doi: 10.1038/s41568-021-00407-4. Epub 2021 Oct 18.

Apoptosis is a form of programmed cell death that is regulated by the balance between prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a hallmark of cancer that arises when this balance is tipped in favour...

Cite
Diepstraten ST, Anderson MA, Czabotar PE, et al. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2021;22(1):45-64doi: 10.1038/s41568-021-00407-4.
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022). The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nature reviews. Cancer, 22(1), 45-64. https://doi.org/10.1038/s41568-021-00407-4
Diepstraten, Sarah T, et al. "The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs." Nature reviews. Cancer vol. 22,1 (2022): 45-64. doi: https://doi.org/10.1038/s41568-021-00407-4
Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022 Jan;22(1):45-64. doi: 10.1038/s41568-021-00407-4. Epub 2021 Oct 18. PMID: 34663943.
Copy Download .nbib Format: NLM
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.

Nature reviews. Cancer

Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL.
PMID: 34663943
Nat Rev Cancer. 2021 Oct 18; doi: 10.1038/s41568-021-00407-4. Epub 2021 Oct 18.

Apoptosis is a form of programmed cell death that is regulated by the balance between prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a hallmark of cancer that arises when this balance is tipped in favour...

Cite
Diepstraten ST, Anderson MA, Czabotar PE, et al. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2021;doi: 10.1038/s41568-021-00407-4.
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2021). The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nature reviews. Cancer, . https://doi.org/10.1038/s41568-021-00407-4
Diepstraten, Sarah T, et al. "The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs." Nature reviews. Cancer vol. (2021). doi: https://doi.org/10.1038/s41568-021-00407-4
Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2021 Oct 18; doi: 10.1038/s41568-021-00407-4. Epub 2021 Oct 18. PMID: 34663943.
Copy Download .nbib Format: NLM
Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review.

JAC-antimicrobial resistance

Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, Meijer AJM.
PMID: 34917943
JAC Antimicrob Resist. 2021 Dec 14;3(4):dlab184. doi: 10.1093/jacamr/dlab184. eCollection 2021 Dec.

BACKGROUND: Ototoxicity has been reported after administration of aminoglycosides and glycopeptides.OBJECTIVES: To identify available evidence for the occurrence and determinants of aminoglycoside- and glycopeptide-related ototoxicity in children.MATERIALS AND METHODS: Systematic electronic literature searches that combined ototoxicity (hearing loss, tinnitus...

Cite
Diepstraten FA, Hoetink AE, van Grotel M, et al. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. 2021;3(4):dlab184doi: 10.1093/jacamr/dlab184.
Diepstraten, F. A., Hoetink, A. E., van Grotel, M., Huitema, A. D. R., Stokroos, R. J., van den Heuvel-Eibrink, M. M., & Meijer, A. J. M. (2021). Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC-antimicrobial resistance, 3(4), dlab184. https://doi.org/10.1093/jacamr/dlab184
Diepstraten, F A, et al. "Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review." JAC-antimicrobial resistance vol. 3,4 (2021): dlab184. doi: https://doi.org/10.1093/jacamr/dlab184
Diepstraten FA, Hoetink AE, van Grotel M, Huitema ADR, Stokroos RJ, van den Heuvel-Eibrink MM, Meijer AJM. Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review. JAC Antimicrob Resist. 2021 Dec 14;3(4):dlab184. doi: 10.1093/jacamr/dlab184. eCollection 2021 Dec. PMID: 34917943; PMCID: PMC8669239.
Copy Download .nbib Format: NLM
An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children.

CPT: pharmacometrics & systems pharmacology

Diepstraten J, Chidambaran V, Sadhasivam S, Blussé van Oud-Alblas HJ, Inge T, van Ramshorst B, van Dongen EP, Vinks AA, Knibbe CA.
PMID: 24026252
CPT Pharmacometrics Syst Pharmacol. 2013 Sep 11;2:e73. doi: 10.1038/psp.2013.47.

This study describes a population pharmacokinetic meta-analysis of propofol to characterize the influence of body size measures and age in morbidly obese and nonobese adults, adolescents, and children. Sixty morbidly obese and nonobese adult patients (55-167 kg; 21-79 years)...

Cite
Diepstraten J, Chidambaran V, Sadhasivam S, et al. An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol. 2013;2:e73doi: 10.1038/psp.2013.47.
Diepstraten, J., Chidambaran, V., Sadhasivam, S., Blussé van Oud-Alblas, H. J., Inge, T., van Ramshorst, B., van Dongen, E. P., Vinks, A. A., & Knibbe, C. A. (2013). An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT: pharmacometrics & systems pharmacology, 2e73. https://doi.org/10.1038/psp.2013.47
Diepstraten, J, et al. "An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children." CPT: pharmacometrics & systems pharmacology vol. 2 (2013): e73. doi: https://doi.org/10.1038/psp.2013.47
Diepstraten J, Chidambaran V, Sadhasivam S, Blussé van Oud-Alblas HJ, Inge T, van Ramshorst B, van Dongen EP, Vinks AA, Knibbe CA. An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol. 2013 Sep 11;2:e73. doi: 10.1038/psp.2013.47. PMID: 24026252; PMCID: PMC4026632.
Copy Download .nbib Format: NLM
Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size.

Clinical pharmacokinetics

Diepstraten J, Chidambaran V, Sadhasivam S, Esslinger HR, Cox SL, Inge TH, Knibbe CA, Vinks AA.
PMID: 28258392
Clin Pharmacokinet. 2012 Aug;51(8):543-551. doi: 10.1007/BF03261930.

BACKGROUND AND OBJECTIVE: Given the alarming increase in obesity among children undergoing surgery, the main aim of this study was to characterize propofol clearance in a cohort of morbidly obese children and adolescents in relation to their age and...

Cite
Diepstraten J, Chidambaran V, Sadhasivam S, et al. Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size. Clin Pharmacokinet. 2012;51(8):543-551doi: 10.1007/BF03261930.
Diepstraten, J., Chidambaran, V., Sadhasivam, S., Esslinger, H. R., Cox, S. L., Inge, T. H., Knibbe, C. A., & Vinks, A. A. (2012). Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size. Clinical pharmacokinetics, 51(8), 543-551. https://doi.org/10.1007/BF03261930
Diepstraten, Jeroen, et al. "Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size." Clinical pharmacokinetics vol. 51,8 (2012): 543-551. doi: https://doi.org/10.1007/BF03261930
Diepstraten J, Chidambaran V, Sadhasivam S, Esslinger HR, Cox SL, Inge TH, Knibbe CA, Vinks AA. Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size. Clin Pharmacokinet. 2012 Aug;51(8):543-551. doi: 10.1007/BF03261930. PMID: 28258392.
Copy Download .nbib Format: NLM
Development and Validation of a Convolutional Neural Network for Automated Detection of Scaphoid Fractures on Conventional Radiographs.

Radiology. Artificial intelligence

Hendrix N, Scholten E, Vernhout B, Bruijnen S, Maresch B, de Jong M, Diepstraten S, Bollen S, Schalekamp S, de Rooij M, Scholtens A, Hendrix W, Samson T, Sharon Ong LL, Postma E, van Ginneken B, Rutten M.
PMID: 34350413
Radiol Artif Intell. 2021 Apr 28;3(4):e200260. doi: 10.1148/ryai.2021200260. eCollection 2021 Jul.

PURPOSE: To compare the performance of a convolutional neural network (CNN) to that of 11 radiologists in detecting scaphoid bone fractures on conventional radiographs of the hand, wrist, and scaphoid.MATERIALS AND METHODS: At two hospitals (hospitals A and B),...

Cite
Hendrix N, Scholten E, Vernhout B, et al. Development and Validation of a Convolutional Neural Network for Automated Detection of Scaphoid Fractures on Conventional Radiographs. Radiol Artif Intell. 2021;3(4):e200260doi: 10.1148/ryai.2021200260.
Hendrix, N., Scholten, E., Vernhout, B., Bruijnen, S., Maresch, B., de Jong, M., Diepstraten, S., Bollen, S., Schalekamp, S., de Rooij, M., Scholtens, A., Hendrix, W., Samson, T., Sharon Ong, L. L., Postma, E., van Ginneken, B., & Rutten, M. (2021). Development and Validation of a Convolutional Neural Network for Automated Detection of Scaphoid Fractures on Conventional Radiographs. Radiology. Artificial intelligence, 3(4), e200260. https://doi.org/10.1148/ryai.2021200260
Hendrix, Nils, et al. "Development and Validation of a Convolutional Neural Network for Automated Detection of Scaphoid Fractures on Conventional Radiographs." Radiology. Artificial intelligence vol. 3,4 (2021): e200260. doi: https://doi.org/10.1148/ryai.2021200260
Hendrix N, Scholten E, Vernhout B, Bruijnen S, Maresch B, de Jong M, Diepstraten S, Bollen S, Schalekamp S, de Rooij M, Scholtens A, Hendrix W, Samson T, Sharon Ong LL, Postma E, van Ginneken B, Rutten M. Development and Validation of a Convolutional Neural Network for Automated Detection of Scaphoid Fractures on Conventional Radiographs. Radiol Artif Intell. 2021 Apr 28;3(4):e200260. doi: 10.1148/ryai.2021200260. eCollection 2021 Jul. PMID: 34350413; PMCID: PMC8329964.
Copy Download .nbib Format: NLM
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.

NPJ precision oncology

Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM.
PMID: 34262104
NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z.

In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss...

Cite
Meijer AJM, Diepstraten FA, Langer T, et al. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021;5(1):64doi: 10.1038/s41698-021-00178-z.
Meijer, A. J. M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., Winther, J. F., Rechnitzer, C., Hasle, H., Kepak, T., Kepakova, K., Tissing, W. J. E., van der Kooi, A. L. F., Kremer, L. C. M., Kruseova, J., Pluijm, S. M. F., Kuehni, C. E., van der Pal, H. J. H., Parfitt, R., Spix, C., Tillmanns, A., Deuster, D., Matulat, P., Calaminus, G., Hoetink, A. E., Elsner, S., Gebauer, J., Haupt, R., Lackner, H., Blattmann, C., Neggers, S. J. C. M. M., Rassekh, S. R., Wright, G. E. B., Brooks, B., Nagtegaal, A. P., Drögemöller, B. I., Ross, C. J. D., Bhavsar, A. P., Am Zehnhoff-Dinnesen, A. G., Carleton, B. C., Zolk, O., van den Heuvel-Eibrink, M. M. (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ precision oncology, 5(1), 64. https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, et al. "TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study." NPJ precision oncology vol. 5,1 (2021): 64. doi: https://doi.org/10.1038/s41698-021-00178-z
Meijer AJM, Diepstraten FA, Langer T, Broer L, Domingo IK, Clemens E, Uitterlinden AG, de Vries ACH, van Grotel M, Vermeij WP, Ozinga RA, Binder H, Byrne J, van Dulmen-den Broeder E, Garrè ML, Grabow D, Kaatsch P, Kaiser M, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, Kepakova K, Tissing WJE, van der Kooi ALF, Kremer LCM, Kruseova J, Pluijm SMF, Kuehni CE, van der Pal HJH, Parfitt R, Spix C, Tillmanns A, Deuster D, Matulat P, Calaminus G, Hoetink AE, Elsner S, Gebauer J, Haupt R, Lackner H, Blattmann C, Neggers SJCMM, Rassekh SR, Wright GEB, Brooks B, Nagtegaal AP, Drögemöller BI, Ross CJD, Bhavsar AP, Am Zehnhoff-Dinnesen AG, Carleton BC, Zolk O, van den Heuvel-Eibrink MM. TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z. PMID: 34262104; PMCID: PMC8280110.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries